You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Citation Tools

Article menu

Download PDFPDF

E-Poster viewings
Trials in Progress
IGCS19-0383
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tewari K, Caceres M, Alexandre J, et al
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
International Journal of Gynecologic Cancer 2019;29:A162.